AYTU BIOPHARMA, INC Total Assets

• AYTU BIOPHARMA, INC showed an increase of +5.2% in Total Assets from 2024 to 2025.
• This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2011: $18.8 thousand | Q1 2012: $16.3 thousand | Q2 2012: $14.0 thousand | Q4 2012: $11.9 thousand | Q1 2013: $13.1 thousand | Q2 2013: $9.4 thousand | Q4 2013: $7.2 thousand | Q1 2014: $5.6 thousand | Q2 2014: $13.5 thousand | Q3 2014: $5.5 thousand | Q4 2014: $11.2 thousand | Q1 2015: $8.0 thousand | Q1 2015: $10.20 million | Q2 2015: $18.19 million | Q3 2015: $21.36 million | Q4 2015: $24.41 million | Q1 2016: $21.99 million | Q3 2016: $15.00 million | Q4 2016: $21.51 million | Q1 2017: $15.92 million | Q3 2017: $21.25 million | Q4 2017: $18.86 million | Q1 2018: $23.37 million | Q3 2018: $17.98 million | Q4 2018: $42.40 million | Q1 2019: $38.34 million | Q3 2019: $31.02 million | Q4 2019: $74.48 million | Q1 2020: $158.95 million | Q3 2020: $141.27 million | Q4 2020: $166.74 million | Q1 2021: $271.56 million | Q3 2021: $227.73 million | Q4 2021: $223.82 million | Q1 2022: $168.83 million | Q3 2022: $150.00 million | Q4 2022: $141.44 million | Q1 2023: $147.22 million | Q3 2023: $132.89 million | Q4 2023: $131.25 million | Q1 2024: $128.86 million | Q3 2024: $115.83 million | Q4 2024: $116.23 million | Q1 2025: $124.20 million | Q2 2025: $124.18 million | Q3 2025: $124.99 million | Q4 2025: $122.00 million.
• Over the full 15 years of available data (2011 to 2025), AYTU BIOPHARMA, INC's Total Assets has grown by 543,629.7%.
• Historical annual values: Fiscal year 2025: $124.18 million | Fiscal year 2024: $118.10 million | Fiscal year 2023: $136.46 million | Fiscal year 2022: $137.62 million | Fiscal year 2021: $265.67 million | Fiscal year 2020: $153.29 million | Fiscal year 2019: $34.72 million | Fiscal year 2018: $21.06 million | Fiscal year 2017: $15.00 million | Fiscal year 2016: $24.34 million | Fiscal year 2015: $18.23 million | Fiscal year 2014: $12.02 million | Fiscal year 2013: $9.7 thousand | Fiscal year 2012: $12.6 thousand | Fiscal year 2011: $22.8 thousand.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026